Pages that link to "Q24616159"
Jump to navigation
Jump to search
The following pages link to Metabolic complications of androgen deprivation therapy for prostate cancer (Q24616159):
Displaying 50 items.
- Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy (Q26864943) (← links)
- Quality of life issues in men undergoing androgen deprivation therapy: a review (Q27002887) (← links)
- Hormone naïve prostate cancer: predicting and maximizing response intervals (Q27015904) (← links)
- The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK (Q28072710) (← links)
- Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy? (Q28081451) (← links)
- A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy (Q33443421) (← links)
- Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events. (Q33763924) (← links)
- High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism (Q34137900) (← links)
- Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer (Q34211155) (← links)
- Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome (Q34227893) (← links)
- Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man (Q34245617) (← links)
- Treatment and prevention of bone complications from prostate cancer (Q34441944) (← links)
- Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer (Q34617904) (← links)
- Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer (Q34617956) (← links)
- Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer (Q34960778) (← links)
- Malignancy-associated dyslipidemia. (Q35030677) (← links)
- A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy (Q35096149) (← links)
- Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study (Q35213928) (← links)
- Castration influences intestinal microflora and induces abdominal obesity in high-fat diet-fed mice. (Q35951804) (← links)
- Sarcopenia during androgen-deprivation therapy for prostate cancer (Q36212442) (← links)
- Diabetes and risk of cancer (Q36637909) (← links)
- New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones (Q36748502) (← links)
- Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). (Q36751550) (← links)
- Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER (Q36800401) (← links)
- Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management (Q37105407) (← links)
- Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. (Q37339472) (← links)
- Metabolic sequelae associated with androgen deprivation therapy for prostate cancer (Q37431937) (← links)
- Androgen deficiency and atherosclerosis: The lipid link (Q37612176) (← links)
- A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer (Q37633545) (← links)
- National survey addressing the information needs of primary care physicians: Side effect management of patients on androgen deprivation therapy. (Q37726879) (← links)
- A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma (Q37727423) (← links)
- Modern Approach to Metabolic Rehabilitation of Cancer Patients: Biguanides (Phenformin and Metformin) and Beyond (Q37783621) (← links)
- Hypogonadism, Erectile Dysfunction, and Type 2 Diabetes Mellitus: What the Clinician Needs to Know (Q37810422) (← links)
- Australian & New Zealand Faculty of Radiation Oncology Genito‐Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma (Q37825625) (← links)
- Androgen regulation of prostate cancer: Where are we now? (Q37836264) (← links)
- Men's Sexual Health and the Metabolic Syndrome (Q37853495) (← links)
- Metformin in prostate cancer: two for the price of one. (Q37855307) (← links)
- Pharmacotherapeutic management of locally advanced prostate cancer: current status (Q37888666) (← links)
- Onset of effects of testosterone treatment and time span until maximum effects are achieved (Q37900796) (← links)
- Positive margins after radical prostatectomy: implications for failure and role of adjuvant treatment (Q37903116) (← links)
- Surgical therapy for intermediate risk prostate cancer (Q37955345) (← links)
- Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care (Q37990639) (← links)
- AST-induced bone loss in men with prostate cancer: exercise as a potential countermeasure (Q38021668) (← links)
- New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists (Q38023124) (← links)
- LHRH Agonists for the Treatment of Prostate Cancer: 2012. (Q38061629) (← links)
- Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? (Q38071012) (← links)
- Zoledronic acid in genitourinary cancer (Q38101500) (← links)
- High-density lipoprotein and prostate cancer: an overview (Q38132333) (← links)
- Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer (Q38183819) (← links)
- Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study (Q38431287) (← links)